Response to clopidogrel and of the cytochrome cyP2c19 gene polymorphismtunisienne.

##plugins.themes.academic_pro.article.sidebar##

Published Sep 5, 2018
Download
pdf
Vol. 96 No. 3 (2018): Issue Mar 2018

##plugins.themes.academic_pro.article.main##

Rim Charfi
Khadija Mzoughi
Miriam Boughalleb
Henda Hosni
Soumaya Kouidhi
Imen Sfar
Nadia Hammami
Ihsen Zaïri
Manel Limam
Chekib Zedini
Anis Klouz
Yousr Gorgi
Maher Kharrat
Hédi Baccar
Sameh Trabelsi

Abstract

Introduction: Clopidogrel (clopi) is a prodrug widely prescribed in the management of coronary artery disease and requires the intervention of hepatic cytochrome P450 2C19 (CYP2C19) for its activation. However, there is interindividual variability in response to clopi despite the use of recommended doses. Thus, the studies have highlighted the effect of the CYP2C19 gene polymorphism or Cyp2C19 gene on the response to clopi and particularly Cyp2C19 * 2 which may be associated with an increased risk of major cardiovascular events or MACE.
Objective: To evaluate the effect of Cyp2C19 * 2 polymorphism on MACE occurrence and hemorrhagic complications in patients treated with clopi.
Methods: We carried out a descriptive longitudinal study including 71 patients placed under clopi for a minimum duration of one month. Genotyping of the Cyp2C19 allele was performed by conventional polymerase chain reaction (PCR). After a follow-up period of 495 ± 183 days, we performed a statistical analysis to evaluate the association between the Cyp2C19 * 2 polymorphism and the occurrence of MACE or hemorrhagic complications.
Results: Among our patients, 51% had an angioplasty, 42% medical treatment and 7% a coronary artery bypass surgery. In our study population, 52% were heterozygous (HTZ), 28% homozygous (HMZ) healthy * 1 / * 1 and 20% HMZ had the loss of function allele * 2 / * 2. The allelic frequency of Cyp2C19 * 2 was 46%. Follow-up mean duration was of 495 ± 183 days. During this period, the prevalence of MACE was 11% and that of hemorrhagic complications was 13%. In our study, we did not observe a significant association between the occurrence of MACE or hemorrhagic complications with the genotype carrying the Cyp2C19 * 2 allele.
Conclusion: Among patients treated with clopi, wearing a Cyp2C19 * 2 function loss allele didn’t seem to be associated with a significantly higher risk of MACE, nor a significantly lower risk of hemorragic complications. This suggests the necessity of larger studies.

Keywords:

Antiaggregant - Clopidogrel - Drug resistance - Genetic polymorphism - Cytochrome P-450 CYP2C19 - Pharmacogenetics

##plugins.themes.academic_pro.article.details##

References

  1. OMS (Organisation mondiale de la santeÌ) (2015). “Maladies cardiovasculaires”. Disponible sur : <http://www.who.int/mediacentre/factsheets/fs317/fr/> (consulteÌ le 28/11/2016).
  2. OMS (Organisation mondiale de la santeÌ) (2016). “ Les maladies cardiaques : premieÌ€re cause de deÌceÌ€s dans le monde et en Tunisie”. Disponible sur : <http://www.lediplomate.tn/les-maladies-cardiaques-premiere-cause-de-deces-dans-le- monde-et-en-tunisie/> (consulteÌ le 1/1/2017).
  3. Saidi O, Ben Mansour N, O'Flaherty M, Capewell S, Critchley JA, Romdhane HB. Analyzing Recent Coronary Heart Disease Mortality Trends in Tunisia between 1997 and 2009. Samuel J-L, editor. PLoS ONE. 2013;8(5):e63202.
  4. Qureshi Z, Hobson AR. Clopidogrel “Resistance”: Where are We Now?: Clopidogrel “Resistance”. Cardiovasc Ther. 2013;31(1):3-11.
  5. Scott SA, Sangkuhl K, Stein CM, Hulot J-S, Mega JL, Roden DM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. Clin Pharmacol Ther. 2013;94(3):317-23.
  6. Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J [En ligne]. 2017 Aout [12/10/2017];[48 pages]. Disponible à l'URL: https://academic.oup.com/eurheartj/article-pdf/doi/10.1093/eurheartj/ehx419/21382744/ehx419.pdf
  7. Committee CS, others. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).The Lancet. 1996;348(9038):1329-39.
  8. Holmes DR, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning.” J Am Coll Cardiol. 2010;56(4):321-41.
  9. SNP [Internet]. [cited 2017 Sep 18]. Available from: http://www.cypalleles.ki.se/cyp2c19.htm
  10. Genetics Home Reference.CYP2C19 gene [En ligne].[18/09/2017]. Disponible à l'URL: https://ghr.nlm.nih.gov/gene/CYP2C19
  11. Abid L, Laroussi L, Bahloul A, Siala A, Abdelhédi R, Kharrat N, et al. Impact of cytochrome P450 2C19*2 polymorphism on the clinical cardiovascular events after stent implantation in patients receiving clopidogrel of a southern Tunisian region.World J Cardiovasc Dis. 2013;03(01):4-10.
  12. Bouassida M, Bouchareb S. Facteurs preÌdictifs de la reÌsistance au clopidogrel. Le 8eÌ€me CongreÌ€s International de Cardiologie et Biotechnologie CARDIOBIOTEC. 28-30 avril 2016), p14.
  13. Haute Autorité de Santé. Bon usage des agents antiplaquettaires. Recommandations de bonne pratique. Paris : HAS ; 2012. plavix-13370.htm [En ligne]. [cited 2017 Sep 18]. Disponible à l'URL: https://www.vidal.fr/Medicament/plavix-13370.htm
  14. AffichageDoc.php [Internet]. [cited 2017 Sep 18]. Available from: http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=68235154&typedoc=R#RcpContreindications
  15. S Jamd V. Pharmacogenomics Study of Clopidogrel by RFLP based Genotyping of CYP2C19 in Cardiovascular Disease Patients in North-East Population of India. J Pharmacogenomics Pharmacoproteomics [En ligne]. 2014 Mai [18/09/2017];05(03). Disponible à l'URL: http://omicsonline.org/open-access/pharmacogenomics-study-clopidogrel-by-rflp-based-genotyping-of-cypc-in-cardiovascular-disease-patients-india-2153-0645-5-132.php?aid=27130
  16. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G-A, et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions. Circulation. 2007;115(17):2344-51.
  17. Société de Chirurgie Vasculaire et endovasculaire de Langue Française. Qu'est-ce qu'un accident vasculaire cérébral ischémique. Paris: SCVE ; 2017.
  18. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium.Circulation. 2011;123(23):2736-47.
  19. Hardy.html [Internet]. [cited 2017 Sep 19]. Available from: http://atlasgeneticsoncology.org/Educ/Hardy.html
  20. Buzoianu AD, Trifa AP, Popp RA, Militaru MS, Militaru CF, BocşanCI et al. Screening for CYP2C19*2, *3 and *4 gene variants in a Romanian population study group. Farmacia. 2010;58(6):806-12.
  21. Abdelhedi R, Bouayed NA, Alfadhli S, Abid L, Rebai A, Kharrat N. Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations. J Genet. 2015;94(4):765-70.
  22. Addad F, Gouider J, Boughzela E, Kamoun S, Boujenah R, Haouala H, et al. Prise en charge de l'infarctus du myocarde en Tunisie : résultats préliminaires du registre FAST-MI Tunisie de la Société tunisienne de cardiologie et de chirurgie cardiovasculaire. Ann Cardiol Angéiologie. 2015;64(6):439-45.
  23. Ben Moussa N. Résistance au clopidogrel: Prévalence, déterminants génétiques et impacts pronostiques dans une cohorte de patients coronariens ï›Thèseï. Médecine : Tunis; 2011.
  24. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375.
  25. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362.
  26. Collet J-P, Hulot J-S, Pena A, Villard E, Esteve J-B, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. The Lancet. 2009;373(9660):309-17.
  27. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, et al. Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent Thrombosis. Am J Cardiol. 2009;103(6):806-11.
  28. Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363(18):1704-14.
  29. Mega JL, Simon T, Collet J, et al. Reduced-function cyp2c19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for pci: A meta-analysis. JAMA. 2010;304(16):1821-30.
  30. Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KAA, et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J. 2012;33(17):2143-50.
  31. Kim HS, Chang K, Koh YS, Park MW, Choi YS, Park CS, et al. CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina. Circ Cardiovasc Genet. 2013;6(5):514-21.
  32. Zhang L, Yang J, Zhu X, Wang X, Peng L, Li X et al. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis. Thromb Res. 2015;135(3):449-58.
  33. Wu Y, Zhang XX, Tian L, Jiang JJ, Xu L, Huang YL et al. Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention [article en chinois]. Zhonghua Xin Xue Guan Bing Za Zhi. 2017;45(5):377-385.
  34. Serrano CV, Ramires JAF, Venturinelli M, Arie S, D'Amico E, Zweier JL, et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression: evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol. 1997;29(6):1276-83.
  35. Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM, Harker LA.Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arterioscler Thromb Vasc Biol. 1992;12(12):1475-87.
  36. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials. 2004;25(26):5681-703.
  37. Motovska Z, Kala P. Benefits and risks of clopidogrel use in patients with coronary artery disease: Evidence from randomized studies and registries. Clin Ther. 2008;30:2191-202.
  38. Janssen PWA, Mol EA, Geene SMC, Barbato E, ten Berg JM. Does percutaneous coronary stent implantation increase platelet reactivity? Blood Rev. 2017;31(5):271-5.
  39. Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006;27(20):2420-5.
  40. Chan MY, Weitz JI, Merhi Y, Harrington RA, Becker RC. Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. J Thromb Thrombolysis. 2009;28(3):366-80.
  41. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. J Am Coll Cardiol. 2010;56(12):919-33.
  42. Harmsze AM, van Werkum JW, Hackeng CM, Ruven HJT, Kelder JC, Bouman HJ et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting: Pharmacogenet Genomics. 2012;22(3):169-75.
  43. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics. 2007;17(12):1057-64.
  44. Frere C, Cuisset T, Morange P-E, Quilici J, Camoin-Jau L, Saut N, et al. Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome. Am J Cardiol. 2008;101(8):1088-93.
  45. Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ. Genotyping. J Am Coll Cardiol. 2010;56(2):112-6.
  46. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. J Am Coll Cardiol. 2016;68(10):1082-115.
  47. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010; 376(9749):1320-8.
  48. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. J Am Coll Cardiol. 2011;58(24):e44-122.
  49. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):2354-94.